The US FDA Upgrades the Purple Book to Assist the Transparency in Biosimilars

 The US FDA Upgrades the Purple Book to Assist the Transparency in Biosimilars

The US FDA Upgrades the Purple Book to Assist the Transparency in Biosimilars

Shots:

  • The US FDA is upgrading the Purple Book by changing it from the current list format to a searchable online database. The FDA has released the first phase that contains information on FDA-licensed biosimilar and interchangeable products along with their reference products
  • The further release of phases will expand the number of FDA-licensed biological products included in the Purple Book online database until the final release, which will include information about all FDA-licensed biological products
  • The expansion & digitization of the Purple Book will make information of FDA-licensed biological products more accessible & transparent for patients, industry users and other stakeholders

Click here, Click here ­to­ read full press release/ article | Ref: US FDA | Image: US FDA

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post